ArthroCare, a developer of minimally invasive surgical products, has receieved CE mark for its WoundWand Debridement Device (WoundWand) for distribution in Europe.

The WoundWand enables necrotic tissue to be removed from a wound in a precise and controlled manner, using ArthroCare‘s patented Coblation technology.

The WoundWand is intended for wound debridement in acute and chronic wounds and wound cleansing by removal of necrotic tissue.

ArthroCare’s products based on its patented Coblation technology, uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue minimising damage to healthy tissue

The WoundWand is not available for sale in the US, the company said.